Susan Cleator

6.6k total citations · 1 hit paper
46 papers, 2.0k citations indexed

About

Susan Cleator is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Susan Cleator has authored 46 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 27 papers in Cancer Research and 10 papers in Surgery. Recurrent topics in Susan Cleator's work include Breast Cancer Treatment Studies (23 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer Genomics and Diagnostics (7 papers). Susan Cleator is often cited by papers focused on Breast Cancer Treatment Studies (23 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer Genomics and Diagnostics (7 papers). Susan Cleator collaborates with scholars based in United Kingdom, United States and Czechia. Susan Cleator's co-authors include R. Charles Coombes, W. Heller, Alan Ashworth, Carlo Palmieri, Mitch Dowsett, Marina Parton, Paul Ziprin, T.J. Powles, Robert Goldin and Trevor J. Powles and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Susan Cleator

44 papers receiving 2.0k citations

Hit Papers

Triple-negative breast cancer: therapeutic options 2007 2026 2013 2019 2007 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susan Cleator United Kingdom 20 996 811 714 362 237 46 2.0k
Sara Bravaccini Italy 27 922 0.9× 659 0.8× 806 1.1× 700 1.9× 215 0.9× 125 2.1k
Tadahiko Shien Japan 24 964 1.0× 767 0.9× 482 0.7× 468 1.3× 216 0.9× 164 1.8k
Mary E. Edgerton United States 21 812 0.8× 781 1.0× 1.3k 1.9× 354 1.0× 163 0.7× 46 2.4k
Tiziana Perin Italy 28 1.2k 1.2× 754 0.9× 599 0.8× 246 0.7× 215 0.9× 94 2.2k
Ricardo Costa United States 22 1.1k 1.1× 540 0.7× 848 1.2× 601 1.7× 204 0.9× 82 2.2k
Huiqin Chen United States 21 1.0k 1.0× 726 0.9× 1.1k 1.5× 543 1.5× 118 0.5× 62 2.2k
Guang‐Yu Liu China 25 1.0k 1.0× 1.1k 1.4× 492 0.7× 348 1.0× 205 0.9× 108 2.1k
Serenella Eppenberger‐Castori Switzerland 29 1.4k 1.4× 864 1.1× 1.3k 1.8× 354 1.0× 152 0.6× 75 2.7k
Julia Beretov Australia 25 858 0.9× 926 1.1× 1.3k 1.8× 410 1.1× 148 0.6× 51 2.4k
Puay‐Hoon Tan Singapore 19 727 0.7× 819 1.0× 843 1.2× 490 1.4× 427 1.8× 25 2.1k

Countries citing papers authored by Susan Cleator

Since Specialization
Citations

This map shows the geographic impact of Susan Cleator's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Cleator with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Cleator more than expected).

Fields of papers citing papers by Susan Cleator

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Cleator. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Cleator. The network helps show where Susan Cleator may publish in the future.

Co-authorship network of co-authors of Susan Cleator

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Cleator. A scholar is included among the top collaborators of Susan Cleator based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Cleator. Susan Cleator is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Simon, James A., Amy Branson, Stephen J. Payne, et al.. (2025). Menopausal hormone therapy for breast cancer patients: what is the current evidence?. Menopause The Journal of The North American Menopause Society. 33(1). 88–117.
2.
Cleator, Susan, et al.. (2025). Tumour volume analysis applied to imaging and histological examinations in breast cancer. European Journal of Surgical Oncology. 51(5). 109578–109578. 2 indexed citations
3.
Balachandran, K., Ashley Brown, Sarah Mahmoud, et al.. (2021). 176P Breast cancer treatment during the first wave of the COVID-19 pandemic at a UK centre. Annals of Oncology. 32. S94–S94. 1 indexed citations
4.
Winter, Helen, Sharmin Rahman, John Conibear, et al.. (2018). Virtual metastatic breast multidisciplinary meeting: The next step in personalised medicine.. Journal of Clinical Oncology. 36(15_suppl). e18794–e18794. 1 indexed citations
5.
Dubash, Suraiya, Kathrin Heinzmann, Francesco Mauri, et al.. (2018). Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 45(13). 2285–2299. 31 indexed citations
7.
Sadideen, Hazim, et al.. (2017). The Safety of Early Adjuvant Internal Mammary Lymph Node Irradiation following Mastectomy and Immediate Autologous Reconstruction. Plastic & Reconstructive Surgery. 141(3). 467e–468e. 3 indexed citations
10.
Patten, Darren K., Daniel Leff, Susan Cleator, et al.. (2012). Is the presence of small volume disease in the sentinel node an indication for axillary clearance?. The Breast. 22(1). 70–73. 2 indexed citations
11.
Palmieri, Carlo, Deep Shah, Jonathan Krell, et al.. (2011). Management and Outcome of HER2-Positive Early Breast Cancer Treated With or Without Trastuzumab in the Adjuvant Trastuzumab Era. Clinical Breast Cancer. 11(2). 93–102. 13 indexed citations
12.
Tsim, Nicole, Andrew J. Healey, Adam E. Frampton, et al.. (2011). Two-Stage Resection for Bilobar Colorectal Liver Metastases: R0 Resection Is the Key. Annals of Surgical Oncology. 18(7). 1939–1946. 34 indexed citations
13.
Krell, Jonathan, Colin R. James, Deep Shah, et al.. (2011). Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome. Clinical Breast Cancer. 11(3). 153–160. 16 indexed citations
14.
Cleator, Susan, Trevor J. Powles, Tim Dexter, et al.. (2006). The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Research. 8(3). R32–R32. 56 indexed citations
15.
Cleator, Susan, Andreas Makris, S. Ashley, Rohit Lal, & T.J. Powles. (2005). Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Annals of Oncology. 16(2). 267–272. 56 indexed citations
16.
Cleator, Susan, Anna Tsimelzon, Alan Ashworth, et al.. (2005). Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Research and Treatment. 95(3). 229–233. 91 indexed citations
17.
Cleator, Susan, Marina Parton, & Mitch Dowsett. (2002). The biology of neoadjuvant chemotherapy for breast cancer.. Endocrine Related Cancer. 9(3). 183–195. 61 indexed citations
18.
Cleator, Susan, et al.. (2001). Pattern of Local Recurrence After Conservative Surgery and Radiotherapy for Soft Tissue Sarcoma. Sarcoma. 5(2). 83–88. 15 indexed citations
19.
Cleator, Susan, Kate Fife, Marilu Nelson, et al.. (2000). Treatment of HIV-associated invasive anal cancer with combined chemoradiation. European Journal of Cancer. 36(6). 754–758. 76 indexed citations
20.
Cleator, Susan, et al.. (1992). An examination of needlestick injury rates, hepatitis B vaccination uptake and instruction on ‘sharps’ technique among medical students. Journal of Hospital Infection. 22(2). 143–148. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026